D
uring the ensuing immunity to invading pathogens, numerous signaling molecules are repurposed to execute specific functions in divergent cellular contexts. Sonic hedgehog (SHH), a pleotropic member of the hedgehog family of signaling molecules, plays key roles in vascular embryonic development (1, 2) , wound healing (3), as well as development of various tissues and organs, including brain, heart, and thymus (4, 5) . Despite a comprehensive understanding of the signaling events participating downstream of SHH, relatively little is known in regard to the nature of genes that mediate cell fate specifications by SHH in immune cells like macrophages. Significantly, recognition and amplification of pathogen-specific signaling events play important roles not only in discriminating the invading microbes but also in regulating explicit immune responses (6) (7) (8) (9) (10) (11) (12) (13) . In this context, integration of key signaling centers modulating immunity to pathogenic mycobacterial infections remains unexplored. However, macrophages as sentinels are known to tailor differential immune responses to infections with pathogenic mycobacteria, including Mycobacterium tuberculosis, Mycobacterium bovis, etc., by utilizing dynamic interplay of signaling networks (14) (15) (16) (17) (18) (19) . We propose SHH signaling to constitute one such signaling network.
Canonical SHH signaling that mediates cell fate decisions requires binding of SHH to its cognate receptor, Patched (PTCH1), resulting in alleviating the inhibition of a seven-pass transmembrane protein, Smoothened (SMO). The resultant conformational changes in SMO lead to the activation of the GLI family of transcription factors, which often act as rate-limiting elements in defining cell fate specifications (20) . In the off state, GLI3, a wellknown inhibitor of the SHH pathway, is subjected to modifications through a cytosolic inhibitory complex comprising glycogen synthase kinase 3␤ (GSK-3␤), which makes GLI3 a transcriptional repressor (21, 22) . However, SMO activation subdues the inhibitory complex, thereby rendering GLI3 inactive and inducing the transactivatory GLI1 functions (23) . Interestingly, NUMB-induced GLI1 ubiquitination contributes to the tight regulation of the SHH pathway to determine cell fate decisions (24) .
In view of the observations described above, we set out to unravel the molecular mechanisms contributing toward pathogenspecific activation of SHH signaling in macrophages. The present investigation demonstrates that M. bovis BCG, a vaccine strain, triggers a robust activation of SHH signaling in macrophages compared to infection with diverse Gram-positive or Gram-negative microbes. This observation was further evidenced in the in vivo scenario with pulmonary tuberculosis (TB) individuals as well as tuberculous meningitis (TBM) patients exhibiting heightened SHH signaling. Furthermore, experiments utilizing anti-tu-mor necrosis factor alpha (anti-TNF-␣) antibody or TNF-␣ receptor antagonist or utilizing TNF-␣-null macrophages clearly show that sustained TNF-␣ secretion by macrophages upon infection with M. bovis BCG is a critical necessity for SHH activation. The TNF-␣-driven SHH signaling downregulates M. bovis BCGinduced Toll-like receptor 2 (TLR2) signaling events, leading to modulation of a battery of genes that regulate various functions of macrophages genes, like Vegf-a, Socs-3, Cox-2, and Mmp-9, and M1 and M2 genes. Importantly, specific microRNAs (miRNAs), miRNA 31 (miR-31) and miR-150, were identified to be the molecular regulators that bring about the negative-feedback loop comprising TLR2-SHH signaling events. SHH signaling-responsive miR-31 and miR-150 target an adaptor protein of TLR2 signaling, MyD88, leading to suppression of TLR2 responses. Thus, the current study illustrates how SHH signaling tightly regulates the kinetics and strengths of M. bovis BCG-specific TLR2 responses, emphasizing a novel role for SHH signaling in host immune responses to mycobacterial infections.
MATERIALS AND METHODS
Cells, mice, and bacteria. Primary macrophages were isolated from peritoneal exudates of C57BL/6 and TLR2 Ϫ/Ϫ mice. Briefly, mice were intraperitoneally injected with 1 ml of 8% Brewer thioglycolate. After 4 days of injection, mice were sacrificed and peritoneal cells were harvested by lavage from peritoneal cavity with ice-cold phosphate-buffered saline (PBS). The cells were cultured in Dulbecco modified Eagle medium (DMEM; Gibco-Invitrogen, USA) containing 10% fetal bovine serum (FBS) for 6 to 8 h, and adherent cells were used as peritoneal macrophages. Bone marrow-derived macrophages (BMDMs) were isolated from femurs and tibias obtained from wild-type (WT) or TNF-␣ Ϫ/Ϫ mice. BMDMs were cultured in DMEM containing 30% L929 fibroblast-conditioned medium for 7 days. The purity of these cells was confirmed by F4/80 staining using fluorescence-activated cell sorting and was found to be Ͼ95%. All transfection studies were carried out with murine RAW 264.7 macrophage-like cells or human monocytic THP1 cells. Human monocytic THP1 cells were differentiated to macrophages by treatment with 5 nM phorbol myristate acetate for 18 h and rested for 3 days prior to infection or treatment. All studies involving mice were carried out after the approval from the Institutional Ethics Committee for animal experimentation, Indian Institute of Science, as well as from the Institutional Biosafety Committee, Indian Institute of Science. M. bovis BCG Pasteur 1173P2, Mycobacterium smegmatis, Staphylococcus aureus, Klebsiella pneumoniae, Bacillus subtilis, Salmonella enterica, Shigella flexneri, and Escherichia coli were grown to mid-log phase and used at a 10 multiplicity of infection (MOI) in all the experiments.
Generation and culture of human macrophages, DCs, and B cells. CD14 ϩ monocyte-derived human macrophages, dendritic cells (DCs), and CD19 ϩ B cells were obtained from healthy donors as described previously (25) . Briefly, human peripheral blood mononuclear cells (PBMCs) were isolated from buffy coats of healthy donors. Monocytes were isolated from PBMCs by immunomagnetic separation using CD14 ϩ microbeads (Miltenyi Biotec, France). The purity of the monocytes was Ͼ98%. These monocytes were differentiated into macrophages or immature DCs by culturing them with L929 cell culture supernatant or interleukin-4 (IL-4; 500 IU/10 6 cells) and granulocyte-macrophage colonystimulating factor (1,000 IU/10 6 cells), respectively, for 7 days in DMEM containing 10% FBS, 50 U/ml penicillin, 50 g/ml streptomycin. CD19 ϩ B cells were isolated from rest of the CD14 Ϫ PBMCs using a cocktail of biotinylated anti-IgG, anti-IgA, and anti-IgM antibodies (The Binding Site Limited, England), followed by immunomagnetic separation with streptavidin microbeads (Miltenyi Biotec). PBMC-derived macrophages, DCs, and B cells were infected with M. bovis BCG for 12 h. This study was approved by the Institutional Bioethics Committee, Indian Institute of Science.
Reagents and antibodies.
General laboratory chemicals were obtained from Sigma-Aldrich (USA) or Merck (Germany). Cell culture medium was obtained from Gibco-Invitrogen. Recombinant human TNF-␣, IL-1␤, IL-18, and IL-6 were purchased from Peprotech. Lipopolysaccharide (LPS), R848, and CpG were purchased from Immunotools (Germany). Anti-COX-2 and anti-PCNA antibodies and TNF-␣ antagonist were purchased from Calbiochem (USA). Anti-␤-actin antibody was purchased from Sigma-Aldrich. Anti-SHH, anti-GLI1, anti-NUMB, anti-Ser9 phospho-GSK-3␤, anti-Tyr458/p55 Tyr199 phospho-p85, anti-p85, anti-Thr37/46 phospho-4EBP1, anti-␣/␤II Thr638/641 phospho-protein kinase C (PKC), anti-␦ Thr505 phospho-PKC, anti-Thr180/Tyr182 phospho-p38 mitogen-activated protein kinase (MAPK), anti-Thr202/Tyr204 phospho-extracellular signal-regulated kinase 1/2 (ERK1/2), anti-ERK1/2, anti-suppressor of cytokine signaling 3 (anti-SOCS-3), anti-matrix metallopeptidase 9 (anti-MMP-9), and antiMyD88 antibodies were purchased from Cell Signaling Technology (USA). Anti-TNF-␣ antibody was purchased from Southern Biotech. Horseradish peroxidase (HRP)-conjugated anti-rabbit IgG and antimouse IgG were obtained from Jackson ImmunoResearch (USA).
Treatment with pharmacological reagents. In all experiments, cells were treated with the given inhibitor for 1 h before experimental treatments with the following concentrations: LY294002 (50 M), rapamycin (100 nM), PKC␣ inhibitor (50 M), PKC␤ inhibitor (20 M), PKC␦ inhibitor (10 M), PKCε inhibitor (50 M), PKC inhibitor (5 M), U0126 (10 M), SB203580 (20 M), SP600125 (50 M), BAY 11-7082 (20 M), purmorphamine (10 M), betulinic acid (10 M), and TNF-␣ antagonist (5 M). Dimethyl sulfoxide (DMSO) at a 0.1% concentration was used as the vehicle control. In all experiments involving pharmacological reagents, a tested concentration was used after careful titration experiments assessing the viability of the macrophages using the MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay.
Enzyme immunoassay. Enzyme immunoassays were carried out in 96-well microtiter plates (Nunc) using cell-free culture supernatant. Vascular endothelial growth factor A (VEGF-A) and TNF-␣ enzyme-linked immunosorbent assay (ELISA) kits were purchased from Peprotech (USA) and BioLegends (USA), respectively. Sandwich ELISAs were performed as per the manufacturer's instruction. Briefly, assay plates were incubated with capture antibody at 4°C overnight. After blocking with 1% bovine serum albumin (BSA) for 1 h at 37°C, wells were incubated with cell-free supernatants for 2 h and then with biotinylated detection antibody for 2 h at 37°C. The wells were further incubated with streptavidin-HRP for 1 h at 37°C and developed with 3,3=,5,5=-tetramethylbenzidine (TMB). The absorbance was measured at 450 nm using an ELISA reader (Molecular Devices, USA).
RNA isolation and quantitative real-time RT-PCR. Macrophages were treated or infected as indicated, and total RNA from macrophages was isolated by TRI reagent (Sigma-Aldrich). Two micrograms of total RNA was converted into cDNA using a first-strand cDNA synthesis kit (Bioline, United Kingdom). Quantitative real-time reverse transcription-PCR (RT-PCR) was performed using a SYBR green PCR mixture (KAPA Biosystems, USA) for quantification of the target gene expression. All the experiments were repeated at least three times independently to ensure the reproducibility of the results. The primers used for quantitative realtime RT-PCR amplification are summarized in Table S1 in the supplemental material.
Immunoblotting. Macrophages were treated or infected as indicated and were lysed in radioimmunoprecipitation assay buffer constituting 50 mM Tris-HCl (pH 7.4), 1% NP-40, 0.25% sodium deoxycholate, 150 mM NaCl, 1 mM EDTA, 1 mM phenylmethylsulfonyl fluoride (PMSF), 1 g/ml each of aprotinin, leupeptin, and pepstatin, 1 mM Na 3 VO 4 , and 1 mM NaF. In case of isolation of the nuclear fraction, the cell pellets were gently lysed in ice-cold buffer A (10 mM HEPES, pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM dithiothreitol [DTT], 0.5 mM PMSF). After incubation on ice for 15 min, the cell membrane was disrupted with 10% NP-40 and the nuclear pellets were recovered by centrifugation at 13,000 rpm for 15 min at 4°C. Nuclear pellets were lysed with ice-cold buffer C (20 mM HEPES, pH 7.9, 0.4 M NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 1 mM PMSF), and nuclear extracts were collected after centrifugation at 13,000 rpm for 20 min at 4°C. An equal amount of protein from each cell or nuclear lysate was resolved in a 12% SDS-polyacrylamide gel and transferred to polyvinylidene difluoride membranes (Millipore, USA) by the semidry transfer (Bio-Rad, USA) method. Nonspecific binding was blocked with 5% nonfat dry milk powder in TBST (20 mM TrisHCl [pH 7.4], 137 mM NaCl, 0.1% Tween 20) for 60 min. The blots were incubated overnight at 4°C with primary antibody, followed by incubation with goat anti-rabbit HRP-conjugated or donkey anti-mouse HRPconjugated secondary antibody in 5% BSA for 2 h. After washing in TBST, the immunoblots were developed with an enhanced chemiluminescence detection system (PerkinElmer, USA) as per the manufacturer's instruction.
Tuberculosis patients and healthy individuals. The study population was comprised of healthy individuals (n ϭ 7) and pulmonary tuberculosis patients (n ϭ 10) reporting to the National Institute of Mental Health and Neurosciences, Bangalore, India. Radiological and clinical examinations were performed on each of the subjects under study to confirm active tuberculosis in pulmonary tuberculosis patients and to exclude individuals with active tuberculosis disease in the case of healthy individuals. The study subjects gave written consent, and the study was approved by the Institutional Bioethics Committee.
miRNA expression profiling. The total RNA was isolated from PBMCs obtained from TB patients and healthy individuals. Using the miRCURY LNA array power labeling kit (Exiqon, Denmark), sample and reference RNAs were fluorescent labeled with Hy3 and Hy5, respectively. The hybridization of sample and reference RNAs was carried out at the Tecan HS4800 hybridization station (Tecan, Austria). The miRCURY LNA array microarray slides were scanned using a G2565BA microarray scanner system (Agilent, USA), and image analysis was performed using ImaGene (version 7.0) software (BioDiscovery, USA). The median ratio of Hy3/Hy5 intensity for replicative spots of each miRNA was calculated, and the fold change in the ratio for TB patients compared with that for the healthy individuals was plotted. Data obtained were analyzed by significance analysis of microarrays (SAM) to identify differentially regulated miRNAs. Additionally, the significant miRNAs that were identified by SAM were subjected to hierarchical clustering analysis (HCA) to identify their pattern of expression in TB patients compared with that in the healthy individuals.
Quantification of miRNA expression. For detection of miR-31, miR-150, and miR-146a by quantitative real-time RT-PCR, total RNA was isolated from infected or treated macrophages or PBMCs using the TRI reagent (Sigma-Aldrich). Quantitative real-time RT-PCR for miR-31, miR-150, and miR-146a was done using TaqMan miRNA assays (Applied Biosystems, USA) as per the manufacturer's instruction. U6 snRNA was used for normalization.
In vivo studies in mice. Each in vivo experiment involved 6 to 8 mice per group. For intracranial inoculation, mice were first anesthetized with intraperitoneal (i.p.) injection of ketamine (6 mg). An intracerebral infection of 10 6 M. bovis BCG bacteria suspended in 50 l sterile PBS was done using a 26-gauge syringe needle. Control mice received 50 l of sterile PBS using the same protocol. After 5 days of inoculation, mouse brain was either processed for immunohistochemical analysis or utilized for RNA analysis of the target genes. For in vivo expression analysis of miR-31, miR-150, and miR-146a, 10 4 M. bovis BCG bacteria or PBS as a vehicle control was injected intravenously into the tail vein of mice. After 7 days of infection, mice were sacrificed to collect spleen and lymph nodes. Alternatively, mice were infected intraperitoneally with 10 6 M. bovis BCG or anti-TNF-␣ antibody (0.1 mg) or TNF-␣ antagonist (50 g) for 12 h and peritoneal macrophages were used for further experiments. Total RNA was isolated from the spleen and lymph nodes or the infected peritoneal macrophages, and expression levels of miR-31, miR-150, and miR-146a were analyzed by quantitative real-time RT-PCR.
MyD88 3= UTR and mutant generation. The full-length 3= untranslated region (UTR) of MyD88 was PCR amplified and cloned into the pmirGLO vector using restriction enzyme pair SacI and XbaI. The miR-31 or miR-150 binding sites in the 3= UTR were mutated by nucleotide replacements through site-directed mutagenesis using the megaprimer inverse PCR method. The forward primer comprised the desired mutation, and respective reverse primers were used to generate the megaprimer. The megaprimer was in turn used to amplify the entire plasmid and generate the ⌬miR-31 and ⌬miR-150 mutants.
Transfection studies. RAW 264.7 or THP1-derived macrophage cells were transfected with 100 nM small interfering RNA (siRNA) or miRNA mimic using Oligofectamine (Invitrogen) according to the manufacturer's instructions. Transfection efficiency was found to be more than 50% in all the experiments, as determined by counting the number of siGLO lamin A/C-positive cells in a microscopic field using a fluorescence microscope. At 72 h posttransfection, the cells were treated or infected as indicated and processed for expression analysis. Myd88, Shh, Gli1, and control siRNAs were obtained from Dharmacon as siGENOME SMARTpool reagents, which contain a pool of four different double-stranded RNA oligonucleotides. miR-31, miR-150, miR-146a, and control mimics, miR-31 siRNA and control siRNA, and miR-150 inhibitor or control inhibitor were purchased from Ambion (USA). RAW 264.7 macrophages or THP1-derived macrophage cells were transiently transfected with dominant-negative (DN) mutant forms of TLR2, p85, PKC␦, and RAF1, the MyD88 3= UTR construct, the MyD88 3= UTR ⌬miR-31, or MyD88 3= UTR ⌬miR-150 using low-molecular-weight polyethylenimine (PEI; Sigma-Aldrich). At 72 h posttransfection, the cells were treated or infected as indicated and processed for immunoblotting or luciferase analysis.
Luciferase assays. For experimental target gene validations, THP1-derived macrophage cells were transfected with the MyD88 3= UTR construct, MyD88 3=UTR ⌬miR-31, or MyD88 3=UTR ⌬miR-150, along with the ␤-galactosidase vector and indicated miRNA mimics or treatments. After 72 h of transfection, cells were lysed in reporter lysis buffer (Promega) and assayed for luciferase activity using luciferase assay reagent (Promega). The results were normalized for transfection efficiencies as determined by ␤-galactosidase activity.
Immunohistochemistry. Microtome sections (4 m) were obtained from formalin-fixed, decalcified, and paraffin-embedded mouse brain tissue samples. These sections were first deparaffinized, subjected to antigen retrieval by boiling in 10 mM citrate buffer (pH 6.0) for 10 min, treated with 1% H 2 O 2 for 10 min, and blocked with 5% BSA for 1 h at room temperature. The tissue sections were further incubated with primary antibodies overnight. After incubation with anti-rabbit HRP-conjugated secondary antibody for 90 min, sections were stained with 0.05% diaminobenzidine (DAB) and 0.03% H 2 O 2 and counterstained with hematoxylin, dehydrated, and mounted. Stained tissue sections were analyzed with a Leica DM LB microscope (Leica Microsystems, Germany). All ex- periments were performed with appropriate isotype-matched control antibodies.
Statistical analysis. Levels of significance for comparison between samples were determined by the Student t test distribution and one-way analysis of variance. The data in the graphs are expressed as the mean Ϯ standard error (SE), and P values of Ͻ0.05 were defined as significant. GraphPad Prism (version 3.0) software (GraphPad Software) was used for all the statistical analysis.
RESULTS
M. bovis BCG-specific TLR2 signaling regulates activation of SHH signaling. The hedgehog (HH) signaling pathway, a novel regulator of cell fate decisions during embryonic development, tumorigenesis, etc., appears to exert significant effects on the initiation, progression, and perpetuation of various disease conditions. SHH, a member of the HH family of signaling molecules, often plays key roles in controlling cell fate decisions across a range of biological systems, including drosophila, mammals, etc., as well as during various other pathophysiological diseases, including cancer (26, 27) . However, the important contributory role for SHH signaling during microbial infections of host macrophages and the manifestation of pathogenesis remains unclear.
In order to elucidate the role of SHH signaling during infections with microbes, macrophages were infected with representative members of pathogenic and nonpathogenic eubacteria. In this screen, M. bovis BCG and M. smegmatis were chosen from the acid-fast bacillus group, and S. aureus, K. pneumoniae, and B. subtilis and S. enterica, S. flexneri, and E. coli were selected to represent Gram-positive and Gram-negative eubacteria, respectively. Among the tested microbes, M. bovis BCG, a vaccine strain, elicits a robust activation of SHH signaling in macrophages compared to infection with the chosen Gram-positive or Gram-negative microbes ( Fig. 1A and B) . The screen involved expression-level analysis of canonical SHH signaling molecules like Shh, Gli1, Gli2, Smo, and Ptch1, which serve as readouts for induced SHH signaling, using real-time quantitative RT-PCR or immunoblotting. Albeit M. bovis BCG demonstrated a significantly higher capacity to activate SHH signaling, nonpathogenic M. smegmatis or selected eubacteria, irrespective of their pathogenic attributes, failed to do the same. Further, M. bovis BCG markedly inhibited the expression and activation of known negative regulators of SHH signaling, NUMB and GSK-3␤ ( Fig. 1B; see Fig. S1A in the supplemental material). Kinetic analysis of expression of canonical members of SHH signaling revealed that M. bovis BCG induced Shh, Gli1, or Gli2 gene expression at lower levels at early times and upregulated gene expression at later time points (Fig. 1C to E) . The augmented expression of Shh, Gli1, or Gli2 coincided with the concomitant inhibition of expression of known negative regulators of SHH signaling, NUMB and GSK-3␤ (see Fig. S1B in the supplemental material). Additionally, nuclear translocation of GLI1 and secretion of the cleaved form of SHH mark the activation of SHH signaling. As shown in Fig. 1F , M. bovis BCG challenge triggered the nuclear translocation of GLI1. The 19-kDa cleaved active form of SHH was detected in both the cell lysate and the corresponding supernatant obtained from M. bovis BCG-infected macrophages (see Fig. S1C in the supplemental material) . Previously, we have demonstrated that pathogen-specific activation of TLR2 upon infection with M. bovis BCG, in comparison to other pathogenic microbes, including S. enterica serovar Typhimurium and S. aureus, programs macrophages for robust upregulation of Wnt-␤-catenin signaling (9) . In this context, macrophages from TLR2-null mice were severely compromised in their ability to trigger M. bovis BCG-induced expression of the effectors of canonical SHH signaling (Fig. 1G) . Similarly, siRNA-mediated knockdown of Myd88 significantly reduced M. bovis BCG-triggered activation of SHH signaling (Fig. 1H) .
Activation of SHH signaling during M. tuberculosis infection. In order to bring relevance to the biology of Mycobacterium infection in vivo, we investigated the expression of SHH signaling in cells derived from tuberculosis patients. Transcript analysis demonstrated higher levels of SHH and GLI1 expression in PBMCs obtained from pulmonary TB patients ( Fig. 2A) . In order to evaluate the role of antigen-presenting cells other than monocytes, which represent ϳ10% of the PBMCs, we isolated macrophages, DCs, and B cells from PBMCs derived from healthy donors. These subsets of cells were challenged with M. bovis BCG, and the expression analysis of SHH signaling signatures was assayed. As illustrated in Fig. 2B , among the antigen-presenting cells, macrophages and DCs exhibited infection-driven SHH signaling, whereas B cells did not. Further, in order to delineate participation of SHH signaling in mycobacterial pathogenesis in vivo, we utilized a well-known mouse model of TBM, wherein mycobacterial bacilli were inoculated intracranially and progressive activation of SHH signaling was analyzed. As evidenced in Fig. 2C , augmented expression of SHH, GLI1, and GLI2 could be detected in mouse brains infected with M. bovis BCG. The immunohistochemical analysis of SHH, GLI1, and PTCH1 in brain tissue samples of TBM patients validated the in vivo induction of SHH signaling (Fig. 2D) .
TNF-␣ is a critical link in activation of Mycobacterium-specific SHH signaling activation. TNF-␣, a first-responder cyto- kine, is released upon infection of macrophages with various microbes, including pathogenic mycobacteria. TNF-␣ exhibits a critical role in host immunity during pathogenic mycobacterial infections and acts as rate-limiting factor for maintenance of granulomas (28) . Importantly, pathogenic as well as nonpathogenic mycobacteria elicit differential levels of TNF-␣ secretion by macrophages. Further, a recent study demonstrates that TNF-␣-mediated regulation of NOTCH signaling by inhibiting NUMB expression is involved in the suppression of FOXA2 transactivation activity (29) . Since NUMB is a known negative regulator of SHH signaling, we explored the contribution of TNF-␣ in M. bovis BCG's ability to induce SHH signaling in macrophages by modulating NUMB activity. As shown in Fig. 3A and B, among the tested microbes, M. bovis BCG infection of macrophages resulted in sustained production of TNF-␣ in a TLR2-dependent manner. Interestingly, TNF-␣ holds the capacity to activate SHH signaling, as evidenced by GLI1 nuclear translocation (Fig. 3C) . To test the sufficiency of TNF-␣ to drive SHH signaling, we analyzed the kinetics of SHH signaling activation in macrophages at different time points as well as at various concentrations of TNF-␣ (Fig. 3D to  G) . The induced expression of SHH, GLI1, GLI2, and PTCH1 at the transcript or protein levels with a concomitant decrease in NUMB or increased phosphorylation of GSK-3␤ advocates for a direct correlation between M. bovis BCG-induced TNF-␣ and robust activation of SHH signaling. Importantly, similar to results obtained with M. bovis BCG infection (Fig. 1C to E) , TNF-␣ treatment induced SHH, GLI1, GLI2, and PTCH1 expression at lower levels at early times, and expression was upregulated at later time points. To validate the role of M. bovis BCG-driven production of TNF-␣ in inducing SHH signaling, macrophages were pretreated with neutralizing anti-TNF-␣ antibody or TNF-␣ receptor antagonist in vitro, followed by infection with M. bovis BCG. Similarly, mice were pretreated with anti-TNF-␣ antibody or TNF-␣ receptor antagonist, followed by infection with M. bovis BCG. As shown in Fig. 4A to F, neutralization of TNF-␣ or blockade of TNF-␣ receptor signaling significantly reduced the infection-induced SHH signaling activation. Importantly, macrophages derived from TNF-␣- null mice significantly compromised M. bovis BCG's ability to induce SHH signaling ( Fig. 4G and H) .
In order to address if TNF-␣-induced SHH operates in an autocrine or paracrine manner, cycloheximide, a well-known protein translational inhibitor, was utilized to pretreat macrophages, followed by infection with M. bovis BCG. The data presented in Fig. S2A in the supplemental material clearly demonstrate that M. bovis BCG-triggered TNF-␣ mRNA expression was unaffected by cycloheximide. However, cycloheximide reduced M. bovis BCG-induced Shh, Gli1, and Ptch1 mRNA levels, implicating the crucial role/necessity of a secretory TNF-␣ in mediating M. bovis BCG-induced SHH signaling. Thus, these results present an interesting dichotomy of SHH signaling in utilizing both autocrine and paracrine attributes to orchestrate M. bovis BCG-driven macrophage function. Further, to address the ability of other inflammatory cytokines, such as IL-1, IL-6, and IL-18, to induce SHH signaling activation, macrophages were treated with recombinant TNF-␣, IL-1␤, IL-6, or IL-18 and examined for the induction of SHH signaling. Among these inflammatory cytokines, TNF-␣ exhibited robust induction of SHH signaling. Interestingly, while IL-18 triggered moderate induction of SHH signaling, IL-1␤ and IL-6 failed to induce transcript expression of Shh, Gli1, Gli2, Ptch1, and Smo (see Fig. S2B in the supplemental material). However, only TNF-␣ could activate SHH signaling, as monitored by GLI1 nuclear translocation (see Fig. S2C in the supplemental material).
SHH signaling acts as negative-feedback loop to restrict TLR2 responses during mycobacterial infection. Macrophages often tailor innate immunity to microbial pathogens by careful orchestration of signaling events triggered by TLR2. From a broader perspective, TLR2 receptor engagement with mycobacteria, including M. bovis BCG, has a direct bearing on cell fate decisions through diligent regulation of a wide range of cellular genes that modulate both innate and adaptive immune responses (see Fig. S3A and B in the supplemental material). As described in Fig.  1C to E and Fig. 3D and G, time-kinetic analysis demonstrated that M. bovis BCG-induced as well as infection-stimulated TNF-␣-induced Shh, Gli1, and Gli2 expression was significantly augmented at later time points. In this regard, we explored whether TNF-␣-driven late-phase activation of SHH signaling could act as a feedback-signaling loop to fine-tune and regulate prolonged TLR2-driven responses. The enforced expression of SHH in macrophages resulted in downregulation of M. bovis BCG-induced phosphoinositide 3-kinase (PI3K), PKC␣, ERK1/2, or p38 MAPK activation (Fig. 5A) . Further, treatment of macrophages with purmorphamine, a pharmacological activator of SHH signaling that leads to constitutive activation of SMO, considerably suppressed M. bovis BCG-dependent TLR2-mediated PI3K, PKC␣, ERK1/2, or p38 MAPK activation (Fig. 5B) . Pharmacological perturbations of TNF-␣-induced SHH signaling by betulinic acid, a known inhibitor of GLI activity, rescued M. bovis BCG's ability to activate PI3K-PKC and MAPK activation (Fig. 5C) . Accordingly, expression of the M. bovis BCG-TLR2-signaling target gene Vegf-A, Socs-3, Mmp-9, or Cox-2 was markedly reduced upon activation of SHH signaling by purmorphamine or TNF-␣. Importantly, pharmacological inhibition of SHH signaling by betulinic acid could rescue the loss of VEGF-A, SOCS-3, MMP-9, or COX-2 or TLR2 signaling ( Fig. 5D and E; see Fig. S3C in the supplemental material). Additionally, experiments utilizing Shh siRNA to block SHH signaling were performed to monitor TLR2 downstream signaling targets. As shown in Fig. 5F and in Fig. S3D in the supplemental material, similar to betulinic acid, knockdown of SHH signaling alleviates TNF-␣-mediated suppression of TLR2 downstream signaling targets, such as VEGF-A, COX-2, SOCS-3, and MMP-9. Thus, these results strongly signify a role for M. bovis BCG-stimulated SHH signaling in exerting an integrated negative-feedback loop to fine-tune and regulate Mycobacterium-specific TLR2 responses.
SHH signaling-driven miR-31 and miR-150 target MyD88. Next, we asked how M. bovis BCG/TNF-␣-induced SHH signaling regulates TLR2 responses. Regulation of innate receptor-triggered signaling networks often requires various checks and balances that are arbitrated by posttranscriptional control mechanisms like those mediated by miRNAs (30) . Importantly, we have recently demonstrated a novel role for miR-155 in orchestrating cellular reprogramming during immune responses to mycobacterial infection (31) . In this regard, we carried out genome-wide expression profiling of miRNAs in PBMCs from TB patients. The profiling identified a number of differentially regulated miRNAs between TB patients and healthy subjects; among these, our investigation focused on expression patterns of significantly deregulated miR-31, miR-150, and miR-146a (Fig. 6A) . Importantly, mice challenged in vivo with M. bovis BCG exhibited enhanced expression of miR-31, miR-150, and miR-146a in spleen, lymph nodes, or peritoneal macrophages in a TLR2-dependent manner ( Fig. 6B and C; see Fig. S4A and B in the supplemental material). Next, we assessed whether M. bovis BCG-induced TNF-␣ is involved in modulation of miR-31, miR-150, and miR-146a expression. As mentioned above for the data shown in Fig. 5 , SHH signaling considerably suppressed M. bovis BCG-TLR2-mediated PI3K, PKC␣, ERK1/2, or p38 MAPK activation or expression of TLR2-responsive genes. In this perspective, the gain-of-function and loss-of-function studies utilizing overexpression of SHH or siRNA to Shh and Gli1 validated the role for TNF-␣-mediated SHH signaling in the expression of miR-31and miR-150 at later time points ( Fig. 6D and E ; see Fig. S4C to E in the supplemental material). However, the activated SHH signaling was dispensable for the regulation of miR-146a expression ( Fig. 6D and E) . Importantly, M. bovis BCG-induced Shh, Gli1, or Gli2 was expressed at lower levels at early times and was upregulated at later time points during infection of macrophages ( Fig. 1C and E) . Consistent with these observations, TNF-␣-induced expression of miR-31 and miR-150 followed a similar pattern of expression as SHH signaling activation at later time points (Fig. 7A and B) . Intriguingly, M. bovis BCG failed to trigger the induction of miR-31 and miR-150 in TNF-␣-null macrophages or in macrophages or mice that were pretreated with anti-TNF-␣ antibody or TNF-␣ receptor antagonist (Fig. 7C to G) . Further, we assessed the function of miR-31 and miR-150 in fine-tuning of TLR2 responses during M. bovis BCG infection. The extensive bioinformatic analyses, including RNA-hybrid analysis, suggested that MyD88, an adaptor molecule important for signaling by many TLRs, is a target for miR-31 and miR-150 (Fig. 8A) . The target sites located at residues spanning residues 152 to 178 (for miR-31) and residues 1598 to 1637 (for miR-150) in Myd88 mRNA are critical for miRNA-3= UTR interactions.
miR-31 and miR-150 modulate TLR2 responses by targeting MyD88. MyD88, as a key anchor adaptor, plays regulatory roles by integrating various signaling events generated by receptor engagement of TLRs. Importantly, MyD88 recruitment to TLR2 results in active recruitment of the p85 regulatory subunit of PI3K, leading to activation of the PI3K pathway (32, 33) . As described, activation of the PI3K pathway leads to modulation of NF-B through a strong collaboration between PKC and MAPK signaling cascades, which culminates in augmented expression of TLR2-responsive genes (9, 10, 15, 18) . In this regard, enforced expression of miR-31 and miR-150, but not miR-146a, resulted in a marked reduction of M. bovis BCGinduced MyD88 expression in a concentration-dependent manner (Fig. 8B) . However, infection-induced Myd88 transcript levels remain unperturbed by ectopic expression of miR-31 or miR-150 (Fig. 8C) . Next, we utilized the WT MyD88 3= UTR and miR-31 and miR-150 binding-site mutants of the MyD88 3= UTR to validate MyD88 as a direct target of miR-31 and miR-150. As shown in Fig. 8D , TNF-␣ treatment or cotransfection with miR-31 or miR-150 mimics markedly reduced WT MyD88 3= UTR luciferase activity. However, repression of luciferase activity was not observed when mutant MyD88 3= UTR luciferase constructs (for miR-31 or miR-150 binding sites) were utilized (Fig. 8D) . These results strongly advocate for the possibility and validate that MyD88 is a direct target of miR-31 and miR-150. Similarly, TNF-␣ treatment or enforced expression of miR-31 or miR-150 significantly reduced M. bovis BCG-TLR2-driven MyD88 expression (Fig. 8E  and F) . Further, as shown in Fig. 9A , expression of miR-31 and miR-150, but not miR-146a, mimics in macrophages strongly repressed M. bovis BCG-driven TLR2 signaling, as evidenced by the activation status of p85 PI3K, 4EBP1, PKC␦, ERK1/2, and p38 MAPKs. Accordingly, miR-31 or miR-150 significantly reduced M. bovis BCG-induced activation of p85 PI3K, 4EBP1, PKC␦, ERK1/2, and p38 MAPK signaling ( Fig. 9B and C) . These results are in agreement with the inhibitory effects on macrophages mediated by TNF-␣ or purmorphamine, an activator of SHH. Importantly, miR-31 or miR-150 inhibited expression of infection-induced TLR2-responsive genes Vegf-A, Socs-3, Mmp-9, and Cox-2, similar to the effects of TNF-␣ or purmorphamine (Fig. 9D to F) . However, transfection of macrophages with miR-31 siRNA or miR-150 inhibitor did not demonstrate a significant change in M. bovis BCG-driven inflammatory gene expression (see Fig. S5 in the supplemental material). These results strongly advocate for the regulatory role of TNF-␣/SHH-triggered miR-31 and miR-150.
Significantly, VEGF-A-and COX-2-derived prostaglandin E 2 influences the polarization of macrophages toward an alternatively activated or M2 phenotype (34) . Similarly, SOCS-3 acts as a negative regulator of signaling induced by several cytokines and Toll-like receptors, thus exhibiting a significant bearing on polarization of macrophages (18) . In this regard, we assessed whether SHH-driven miR-31 and miR-150 influence the determination of M1 versus M2 polarization of macrophages. In a TLR2-dependent manner, M. bovis BCG triggers the expression of various M1 (Inos, Tnf-␣, Ccl5 , and Cxcl9) and M2 (Il-10, Arg-1, Ho-1, and Ccl17) genes that play critical roles in the determination of M1 versus M2 polarization of macrophages ( Fig. 10A; Fig. 10C and D; see Fig. S6C to D in the supplemental material). However, extensive time-kinetics analysis did not reveal any definitive signatures of macrophage polarization. Together, these results identify a balancing act of SHH signaling-activated miR-31 and miR-150 in fine-tuning a defined set of effector functions of macrophages during Mycobacterium-specific TLR responses.
DISCUSSION
Our investigations identify a unique role for SHH signaling in regulating innate recognition of M. bovis BCG among various microbial pathogens by macrophages. Importantly, identification of SHH signaling as a recognition module that effectively regulates miR-31 and miR-150 targeting of various TLR2 responses shows that it constitutes a significant check and balance that shapes the course of mycobacterial infection. In this context, we show for the first time that Mycobacterium-specific TLR2 signaling effectuates rapid enrichment of the proinflammatory cytokine milieu of TNF-␣ to induce strong SHH signaling activation both in vitro and in vivo. Activation of PKC/MAPK is requisite for SHH signaling (35) , and TNF-␣-induced NF-B modulates SHH signaling (36) . Our work herein further implies the role of TLR2 signaling in orchestrating SHH activation through the infection-induced TNF-␣. Besides the numerous developmental functions attributed to SHH signaling, the present study has delineated the very role of such an indispensable signaling pathway in immune cells like macrophages so that they may carry out their functions effectively.
TLR2-mediated signaling events constitute a number of tight negative-feedback regulations that in turn subdue the downstream effectors of the pathway (37) (38) (39) (40) . Latest in the list are the miRNAs that fine-tune the initiation, amplification, as well as kinetics of immune responses of macrophages or dendritic cells triggered by various TLRs, including TLR2 (41) . Further, miRNAs regulate several cellular processes, including the efficiency and polarization of pathogen-specific inflammatory responses (42) . In this regard, whole-genomic miRNA expression profile analysis demonstrated significant deregulation of miR-31, miR-146a, and miR-150 in tuberculosis patients, which could advocate for a potential role in fine-tuning of host immune responses. Accordingly, in vivo and in vitro experiments demonstrated that miR-31 and miR-150, but not miR-146a, are M. bovis BCG/TNF-␣-driven SHH responsive. Emphasizing the temporal regulation, the coincidence of elevated levels of miR-31 and miR-150 with the TNF-␣-induced SHH signaling at the later time points provided a cue for the potential existence of a negative-feedback loop (Fig. 11) .
Importantly, miR-31 and miR-150, but not miR-146a, target MyD88, an adaptor of TLR2 signaling. In this perspective, our results constitute M. bovis BCG-induced SHH signaling to be a fine-tuner of pathogen-specific TLR2 signaling events that eventually calibrate as well as account for crucial determinants that shape the course of infection. Interestingly, mycobacteria are known to suppress the ability of infected cells to exhibit strong immune responses. For example, infection of macrophages prior to treatment with LPS, a TLR4 agonist, blocked the macrophage responsiveness to TNF-␣ production (25) . Similarly, M. avium subsp. paratuberculosis infection of monocytes showed a marked suppression of classical TLR9-mediated responses (43) . Further, M. tuberculosis infection led to suppression of T-cell responses and apoptosis of Mycobacterium-specific CD4 ϩ T cells in vivo (44, 45) . Similarly, M. bovis BCG infection led to a significant reduction of TLR4 and TLR7/8 ligand-driven expression of an antimicrobial peptide (cathelicidin), a lysosomal aspartyl protease (cathepsin D), and IL-6 (see Fig. S7 in the supplemental material) . Notably, these TLR-responsive genes play important roles in cell fate decisions, including clearance of pathogens.
Taken together, our findings suggest that M. bovis BCG-induced TNF-␣/SHH-driven miR-31 and miR-150 regulate the TLR2 responses, as exemplified by the downstream effectors VEGF-A, SOCS-3, MMP-9, and COX-2, as well as inducible nitric oxide synthase (iNOS), TNF-␣, IL-6, IL-12, CCL5, CXCL9, IL-10, ARG-1, HO-1, and CCL17. However, it is interesting to observe various degrees of suppression of TLR2-responsive M1/M2 genes with the expression of miR-31 and miR-150, emphasizing the sig- nificance of fine-tuning of signals to determine the outcome of the infection. Importantly, the molecular regulators identified in the present study, SHH effectors as well as miR-31 and miR-150, can fuel the search for attractive and effective drug targets to combat diseases of the hour, like tuberculosis.
